Federica Tamburrino

Federica Tamburrino

Auto-generated profile, based on publicly available information

Federica Tamburrino

Pediatric Unit IRCCS Azienda Ospedaliero‐Universitaria di Bologna Bologna Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2013 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
LMLaura Mazzanti
Laura Mazzanti
FTFederica Tamburrino
Federica Tamburrino
ESEmanuela Scarano
Emanuela Scarano
APAnnamaria Perri
Annamaria Perri
BVBenedetta Vestrucci
Benedetta Vestrucci
MTMarco Tartaglia
Marco Tartaglia
Noonan‐like syndrome with loose anagen hair (NS/LAH or Mazzanti Syndrome) is caused by a single missense mutation in SHOC2 promoting tN‐myristoylation of the encoded protein. Cardinal features include facial features resembling NS, short stature often associated with proven growth hormone deficiency (GHD), typical ectodermal anomalies, and distinctive behavior. Overall, the clinical features are more severe than those generally observed in NS, even though the phenotype improves with age. We report on growth and pubertal trend in seven patients heterozygous for a mutated SHOC2 allele, treated with long‐term GH‐therapy, and final height (FH) in three of them. They were approximately −3 SDS below the Italian general population standards, they had very low IGF1 levels at baseline and GHD at pharmacological tests. All patients were treated with GH (0.035 mg/kg/day) for a mean period of 8.49 ± 5.72 years. After the 1st year of GH‐therapy, IGF1 level and height velocity had increased. Three of 7 patients reached the FH (−2.34 ± 0.12 SDS) at 18.25 ± 0.73 years, after GH administration for 12.39 ± 2.12 years. Pubertal development was variable, showing a prolonged and delayed puberty or rapid pubertal progression that could impair the FH. Overall, our data in this small cohort suggest that NS/LAH patients benefit from long‐term GH‐therapy, although they do not show the characteristic catch‐up growth of isolated GHD. While the observed growth and pubertal behavior is consistent with a dysfunction of the hypothalamic‐pituitary‐gonadal axis, the functional link between SHOC2 and the GH/IGF signaling pathways remains to be clarified.

19 November 2022 in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Verified
Journal Article
Closed access
FTFederica Tamburrino
Federica Tamburrino
ESEmanuela Scarano
Emanuela Scarano
CSConcetta Schiavariello
Concetta Schiavariello
APAnnamaria Perri
Annamaria Perri
Andrea PESSIONAndrea PESSION
Andrea PESSION
LMLaura Mazzanti
Laura Mazzanti

31 July 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
FTFederica Tamburrino
Federica Tamburrino
LMLaura Mazzanti
Laura Mazzanti
ESEmanuela Scarano
Emanuela Scarano
DGDino Gibertoni
Dino Gibertoni
MSMaria Sirolli
Maria Sirolli
APAndrea Pession
Andrea Pession
Background: RASopathies are developmental disorders caused by dysregulation of the RAS-MAPK signalling pathway, which contributes to the modulation of multiple extracellular signals, including hormones and growth factors regulating energetic metabolism, including lipid synthesis, storage, and degradation.Subjects and methods: We evaluated the body composition and lipid profiles of a single-centre cohort of 93 patients with a molecularly confirmed diagnosis of RASopathy by assessing height, BMI, and total cholesterol, HDL, triglycerides, apolipoprotein, fasting glucose, and insulin levels, in the context of a cross sectional and longitudinal study. We specifically investigated and compared anthropometric and haematochemistry data between the Noonan syndrome (NS) and Mazzanti syndrome (NS/LAH) groups.Results: At the first evaluation (9.5 ± 6.2 years), reduced growth (-1.80 ± 1.07 DS) was associated with a slightly reduced BMI (-0.34 DS ± 1.15 DS). Lipid profiling documented low total cholesterol levels (< 5th percentile) in 42.2% of the NS group; in particular, in 48.9% of PTPN11 patients and in 28.6% of NS/LAH patients compared to the general population, with a significant difference between males and females. A high proportion of patients had HDL levels lower than the 26th percentile, when compared to the age- and sex-matched general population. Triglycerides showed an increasing trend with age only in NS females. Genotype-phenotype correlations were also evident, with particularly reduced total cholesterol in about 50% of patients with PTPN11 mutations with LDL-C and HDL-C tending to decrease during puberty. Similarly, apolipoprotein A1 and apolipoprotein B deficits were documented, with differences in prevalence associated with the genotype for apolipoprotein A1. Fasting glucose levels and HOMA-IR were within the normal range.Conclusion: The present findings document an unfavourable lipid profile in subjects with NS, in particular PTPN11 mutated patients, and NS/LAH. Further studies are required to delineate the dysregulation of lipid metabolism in RASopathies more systematically and confirm the occurrence of previously unappreciated genotype-phenotype correlations involving the metabolic profile of these disorders.

20 October 2025 in Journal of Intellectual Disability Research
Verified
Journal Article
Open access
MHMirthe J. Klein Haneveld
Mirthe J. Klein Haneveld
KŚKatarzyna Świeczkowska
Katarzyna Świeczkowska
TGTomasz Grybek
Tomasz Grybek
KLKinga Labunets
Kinga Labunets
TAThérèse A. M. J. van Amelsvoort
Thérèse A. M. J. van Amelsvoort
AEAgnies M. Van Eeghen
Agnies M. Van Eeghen
Background: For young people with rare genetic neurodevelopmental disorders associated with intellectual disabilities, the transfer from paediatric to adult healthcare providers is often complicated. The European Reference Network ERN‐ITHACA (Intellectual disability, TeleHealth, Autism and Congenital Anomalies) on Rare Congenital Malformations and Rare Intellectual Disability aims to improve this transition through the development of a guideline. Method: Population‐specific recommendations for the optimal transition to adult healthcare were developed by an interdisciplinary consortium, representing clinical, scientific and lived experience experts from nine European countries. Recommendations of the 2016 National Institute for Health and Care Excellence (NICE) guideline ‘Transition From Children's to Adults' Services for Young People Using Health or Social Care Services’ (NG43) were adapted, based on a literature review, expert opinion and lived experiences gathered through a survey, focus groups and discussions with self‐advocates. A consensus meeting was held in Gdańsk, Poland, in October 2024. Results: NICE guideline recommendations were adopted or adapted to the target population where necessary. New recommendations were formulated regarding the involvement of and assistance for young people and their families/caregivers, the coordination of interdisciplinary care, the role of centres of expertise, recommended interventions and psychosocial support. Conclusions: Planned, coordinated, specialised, individualised and interdisciplinary healthcare is required to support young people with (genetic) intellectual disabilities. Active collaboration between healthcare providers, researchers and individuals with lived experience is essential both to improve current healthcare and to build a stronger evidence base for successful transition interventions going forward.

17 January 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
FTFederica Tamburrino
Federica Tamburrino
LMLaura Mazzanti
Laura Mazzanti
DGDino Gibertoni
Dino Gibertoni
CSConcetta Schiavariello
Concetta Schiavariello
APAnnamaria Perri
Annamaria Perri
ESEmanuela Scarano
Emanuela Scarano
Background: RASopathies, including Noonan syndrome and related disorders, are multisystem conditions caused by mutations in various genes encoding proteins involved in the RAS/MAPK signaling pathway resulting in increased signal flow. They are clinically characterized by failure to thrive, facial dysmorphisms, congenital heart defects, lymphatic malformations, skeletal anomalies, and variable cognitive impairment, with variable prevalence in the different conditions and subtypes. Pubertal development, which affects growth and final height, is often delayed in Noonan syndrome patients, though not universally. This study aimed to evaluate the timing and progression of puberty and its impact on growth and final height in patients with RASopathies.Subjects and methods: A retrospective longitudinal study was conducted involving 103 patients with molecularly confirmed RASopathies. A subgroup of 40 patients who had completed pubertal development was analyzed. Anthropometric, hormonal (FSH, LH, estradiol/testosterone), and radiological data were collected.Results: Among the 40 patients who had completed puberty, 75% had a diagnosis of Noonan syndrome. The median age at pubertal onset was 11.8 years in males and 13.2 years in females. Delayed puberty was observed in 27.8% of patients, with a higher incidence in females. Median final height was significantly lower in those with delayed pubertal onset compared to those with normal development (p < 0.01). No significant differences in final height were observed between patients with growth hormone deficiency treated with growth hormone and those who were untreated.Conclusions: Delayed pubertal onset negatively impacts final height in patients with RASopathies, with inadequate pubertal catch-up growth being a common outcome. While most patients initiate puberty spontaneously, careful monitoring of growth and pubertal progression is crucial to optimize therapeutic interventions and improve final height outcomes.